Oral administration of soluble β-glucans extracted from Grifola frondosa induces systemic antitumor immune response and decreases immunosuppression in tumor-bearing mice

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 108-119

  Masuda, Yuki ^a   Inoue, Hiroko ^a   Ohta, Hiroya ^b   Miyake, Ayumi ^b   Konishi, Morichika ^a,b   Nanba, Hiroaki ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

glucan; dectin 1; Grifola frondosa; oral administration

Indexed keywords

BETA GLUCAN; DECTIN 1; GRIFOLA FRONDOSA EXTRACT; HERBACEOUS AGENT; MAITAKE D FRACTION; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ISOLATION; EXPERIMENTAL MOUSE; FEMALE; GRIFOLA FRONDOSA; IMMUNOSTIMULATION; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BETA-GLUCANS; CYTOKINES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GRIFOLA; IMMUNE TOLERANCE; IMMUNITY, INNATE; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84876673984     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27999     Document Type: Article

References (48)

1. Vollmer J, Krieg AM,. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61: 195-204.
2. Jung ID, Jeong SK, Lee CM, et al. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist. Cancer Res 2011; 71: 2858-70.
3. Chihara G, Hamuro J, Maeda Y, et al. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom). Cancer Res 1970; 30: 2776-81.
4. Lu H, Yang Y, Gad E, et al. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res 2011; 17: 67-76.
5. Tsoni SV, Brown GD,. beta-Glucans and dectin-1. Ann N Y Acad Sci 2008; 1143: 45-60.
6. Nanba H, Hamaguchi A, Kuroda H,. The chemical structure of an antitumor polysaccharide in fruit bodies of Grifola frondosa (maitake). Chem Pharm Bull (Tokyo) 1987; 35: 1162-8.
7. Masuda Y, Inoue M, Miyata A, et al. Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice. Int Immunopharmacol 2009; 9: 620-6.
8. Masuda Y, Togo T, Mizuno S, et al. Soluble beta-glucan from Grifola frondosa induces proliferation and Dectin-1/Syk signaling in resident macrophages via the GM-CSF autocrine pathway. J Leukoc Biol 2012; 91: 547-56.
9. Ito K, Masuda Y, Yamasaki Y, et al. Maitake beta-glucan enhances granulopoiesis and mobilization of granulocytes by increasing G-CSF production and modulating CXCR4/SDF-1 expression. Int Immunopharmacol 2009; 9: 1189-96.
10. Lin H, de Stanchina E, Zhou XK, et al. Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. Cancer Immunol Immunother 2010; 59: 885-97.
11. Deng G, Lin H, Seidman A, et al. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol 2009; 135: 1215-21.
12. Kunisawa J, Kurashima Y, Kiyono H,. Gut-associated lymphoid tissues for the development of oral vaccines. Adv Drug Deliv Rev 2011; 64: 523-30.
13. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
14. Rahir G, Moser M,. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother 2012; 61: 751-9.
15. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
16. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
17. Palucka K, Banchereau J,. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-77.
18. Masuda Y, Ito K, Konishi M, et al. A polysaccharide extracted from Grifola frondosa enhances the anti-tumor activity of bone marrow-derived dendritic cell-based immunotherapy against murine colon cancer. Cancer Immunol Immunother 2010; 59: 1531-41.
19. Qian J, Zheng Y, Zheng C, et al. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 2012; 119: 161-9.
20. Masuda Y, Matsumoto A, Toida T, et al. Characterization and antitumor effect of a novel polysaccharide from Grifola frondosa. J Agric Food Chem 2009; 57: 10143-9.
21. Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077-85.
22. Hernanz-Falcon P, Joffre O, Williams DL, Reis e Sousa C,. Internalization of Dectin-1 terminates induction of inflammatory responses. Eur J Immunol 2009; 39: 507-13.
23. Dillon S, Agrawal S, Banerjee K, et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest 2006; 116: 916-28.
24. Kamiryo Y, Yajima T, Saito K, et al. Soluble branched (1,4)-beta-D-glucans from Acetobacter species enhance antitumor activities against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer 2005; 115: 769-76.
25. Rice PJ, Adams EL, Ozment-Skelton T, et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther 2005; 314: 1079-86.
26. Sandvik A, Wang YY, Morton HC, et al. Oral and systemic administration of beta-glucan protects against lipopolysaccharide-induced shock and organ injury in rats. Clin Exp Immunol 2007; 148: 168-77.
27. Hong F, Yan J, Baran JT, et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 2004; 173: 797-806.
28. Li B, Cai Y, Qi C, et al. Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res 2010; 16: 5153-64.
29. Leibundgut-Landmann S, Osorio F, Brown GD, et al. Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 2008; 112: 4971-80.
30. LeibundGut-Landmann S, Gross O, Robinson MJ, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8: 630-8.
31. Qi C, Cai Y, Gunn L, et al. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived {beta}-glucans. Blood 2011; 117: 6825-36.
32. Salvador C, Li B, Hansen R, et al. Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res 2008; 14: 1239-47.
33. Palma AS, Feizi T, Zhang Y, et al. Ligands for the beta-glucan receptor, Dectin-1, assigned using "designer" microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysaccharides. J Biol Chem 2006; 281: 5771-9.
34. Goodridge HS, Reyes CN, Becker CA, et al. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature 2011; 472: 471-5.
35. Huang H, Ostroff GR, Lee CK, et al. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun 2009; 77: 1774-81.
36. Harada T, Miura NN, Adachi Y, et al. Highly expressed dectin-1 on bone marrow-derived dendritic cells regulates the sensitivity to beta-glucan in DBA/2 mice. J Interferon Cytokine Res 2008; 28: 477-86.
37. Goodridge HS, Shimada T, Wolf AJ, et al. Differential use of CARD9 by dectin-1 in macrophages and dendritic cells. J Immunol 2009; 182: 1146-54.
38. Parti RP, Loper R, Brown GD, et al. Cytosolic phospholipase a2 activation by Candida albicans in alveolar macrophages: role of dectin-1. Am J Respir Cell Mol Biol 2010; 42: 415-23.
39. Qu Y, Chen L, Pardee AD, et al. Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. J Immunol 2010; 185: 2895-902.
40. Pardee AD, McCurry D, Alber S, et al. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res 2010; 70: 9041-52.
41. Bos R, Sherman LA,. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010; 70: 8368-77.
42. Lin YS, Huang LD, Lin CH, et al. In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator. J Biol Chem 2011; 286: 43782-92.
43. Giermasz AS, Urban JA, Nakamura Y, et al. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 2009; 58: 1329-36.
44. Zhou L, Chong MM, Littman DR,. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009; 30: 646-55.
45. Chang LY, Lin YC, Mahalingam J, et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res 2012; 72: 1092-102.
46. Couper KN, Blount DG, Riley EM,. IL-10: the master regulator of immunity to infection. JImmunol 2008; 180: 5771-7.
47. Wu L, Yan C, Czader M, et al. Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 2012; 119: 115-26.
48. Cortez-Retamozo V, Etzrodt M, Newton A, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A 2012; 109: 2491-6.